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E-mail: rdecoo@maastrichtuniversity.nlMitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is an autosomal recessivedisorder caused by thymidine
phosphorylase (TP) deficiency resulting in systemic accumula-
tion of thymidine (d-Thd) and deoxyuridine (d-Urd) and charac-
terized by early-onset neurological and gastrointestinal symp-
toms. Long-term effective and safe treatment is not available.
Allogeneic bone marrow transplantation may improve clinical
manifestations but carries disease and transplant-related risks.
In this study, lentiviral vector-based hematopoietic stem cell
gene therapy (HSCGT) was performed in Tymp/Upp1/
mice with the human phosphoglycerate kinase (PGK) promoter
drivingTYMP. SupranormalbloodTPactivity reduced intestinal
nucleoside levels significantly at low vector copy number (me-
dian, 1.3; range, 0.2–3.6). Furthermore, we covered two major
issues not addressed before. First, we demonstrate aberrant
morphology of brain astrocytes in areas of spongy degeneration,
whichwas reversed byHSCGT. Second, long-term follow-up and
vector integration site analysis were performed to assess safety of
the therapeutic LV vectors in depth. This report confirms and
supplementspreviousworkon the efficacyofHSCGTinreducing
the toxicmetabolites inTymp/Upp1/mice, using a clinically
applicable gene transfer vector and ahighly efficient gene transfer
method, and importantly demonstrates phenotypic correction
with a favorable risk profile, warranting further development
toward clinical implementation.
INTRODUCTION
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
is an autosomal recessive disease caused by mutations in the thymi-152 Molecular Therapy: Methods & Clinical Development Vol. 8 March
This is an open access article under the CC BY-NC-ND license (httpdine phosphorylase gene (TYMP),1 which result in partial or com-
plete deficiency of the enzyme thymidine phosphorylase (TP).2 TP
deficiency results in systemic accumulation of the substrates d-Thd
and d-Urd in plasma and tissues of MNGIE patients3 and thereby
to imbalances in intra-mitochondrial deoxyribonucleoside triphos-
phate pools (dNTPs), which has been considered to induce somatic
mitochondrial DNA alterations in tissues of MNGIE patients.4,5
The clinical spectrum of MNGIE ranges from mild symptoms in
late-onset cases6 to early-teenage onset with fatal malabsorption
and intestinal dysmotility.7 The typical symptoms include ptosis
and ophthalmoplegia, gastrointestinal dysmotility, neuropathy with
reduced sensory-motor conduction, as well as central nervous system
anomalies.4,8 The latter manifest on brain MRI as a unique pattern of
progressive symmetrical cerebral (and occasionally cerebellar) hyper-
intense signal changes on T2-weighted images.9 The available treat-
ment options forMNGIE such as peritoneal dialysis, platelet infusion,
and enzyme replacement therapy fail to achieve persistent clinical
improvement.10–12 As a long-term solution, allogeneic hematopoietic
stem cell transplantation (HSCT) has been proposed; however, this
is associated with high mortality rates due to disease and trans-
plant-related complications.13,14 Recently, liver transplantation has
emerged as a promising treatment option, preferably for patients2018 ª 2018 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Lentiviral Vectors and Design of Transplantation Experiments and TP Expression in the Target Cells
(A) Third-generation self-inactivating LV vectors used in the study and their elements are shown. pCCL and pRRL, LV vectors containing CMV-HIV or RSV-HIV 50 long terminal
repeats, respectively; RRE, Rev response element; cPPT, central polypurine tract; hPGK, human phosphoglycerate kinase promoter; hTP, native coding sequence of the
human TYMP cDNA; hTPco, codon-optimized sequence; IRES, internal ribosome entry site; SF, spleen focus forming virus promoter; WPRE, Woodchuck hepatitis
posttranscriptional regulatory element; bPRE4*, adapted form ofWPRE.38 (B) Design of HSC transplantation experiments. The hematopoietic stem and progenitor cells (Lin)
(legend continued on next page)
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Molecular Therapy: Methods & Clinical Developmentwith pre-existing liver failure; this, however, requires a matched organ
donor and long-term immunosuppression.15 Autologous hematopoi-
etic stem cell gene therapy (HSCGT) could be beneficial for MNGIE
patients as a single intervention with low-dose conditioning and poses
no risks of graft rejection or graft-versus-host disease. Third-genera-
tion self-inactivating lentiviral (LV) vectors are currently used suc-
cessfully in clinical trials for other metabolic disorders.16–18 The
present study supplements and confirms previous reports19,20 by us-
ing (1) a highly efficient transduction method, (2) clinically applicable
LV vectors to evaluate the therapeutic efficacy to reverse the biochem-
ical phenotype and extends these reports by demonstrating (3) ther-
apeutic efficacy of HSGCT in reversing pathological changes, partic-
ularly those of the brain, and assessing (4) potential adverse effects
such as pheno- and genotoxicity.
RESULTS
LV Vectors, Experimental Design, TP Expression, and Enzyme
Activity in Target Cells
Similar to previous studies,19–21 Tymp/Upp1/ mice (referred to
here as KO [knockout]) were used. Unlike in humans, murine uridine
phosphorylase degrades Thd and d-Urd, therefore Tymp/Upp1/,
rather than Tymp/ mice,22 reflect the biochemical phenotype of
MNGIE patients. A LV vector containing both TP and GFP sequences
(PGK-TP-GFP) was reported previously19 for biochemical correction
in Tymp/Upp1/mice and is used in this study as a control. In the
present study, third-generation self-inactivating LVs containing a
similar backbone as currently used in clinical trials for metachromatic
leukodystrophy (MLD)17 andWiskott-Aldrich syndrome23 were con-
structed for expression of TP. The human cellular phosphoglycerate
kinase (hPGK) promoter was used to drive expression of the native
human TYMP sequence (TP) as well as the re-coded human TYMP
sequence (TPco) in the therapeutic vectors, as well as to drive expres-
sion of the GFP transgene in the sham control vector (Figure 1A). The
rationale for using TPco was to enhance protein production with a
minimum number of transduced donor cells and vector copy num-
ber, as reported for IL2RG and RAG2.24,25 The strong spleen focus
forming (SF) virus promoter, which may contribute to leukemic
events by transactivating proto-oncogenes,26 was used to evaluate po-
tential phenotoxicity by excessive overexpression of TYMP and/or
genotoxicity rather than an option for potential clinical application
(Figure 1A).
Two virus concentrations (MOI) were used for transduction, i.e.,
MOIs of 3 or 10. By transplantation experiments (Figure 1B), the ef-
ficiency of the therapeutic LVs (PGK-TP, TPco) were evaluated forfrom male donor mice were ex vivo transduced overnight by the LV vector constructs an
LAM-PCR and integration site analysis were performed on a fraction of the transduced c
To evaluate LV vector-related insertional transformation in vivo, Lin cells from each pr
transplanted mice received 6Gy total body irradiation 24 hr prior to transplantation. A
analysis: sample collection for biochemical and molecular analysis and flow cytometry
expression and activity in KO Lin cells transduced (MOI 10) and cultured in vitro. (C) qP
for VCN/cell. The horizontal line represents the median, n = 3–4 replicates. (D) Western
n = 1; n.a., not applicable. Included also are lysates of SF-TPco-treated cells confirmin
154 Molecular Therapy: Methods & Clinical Development Vol. 8 March(1) biochemical correction (MOI 3 or 10) and (2) neurological correc-
tion as assessed by brain MRI, pathology, and behavioral tests (MOI
10). To assess the safety of HSCGT, primary recipients were subjected
to long-term follow-up for potential transgene overexpression-related
phenotoxicity (in particular in the SF-TPco treatment group) and
LV-related genotoxicity, as well as an integration site analysis of
gene-modified cells prior to and after engraftment in primary recip-
ient mice aged 13 months, i.e., 11 months after HSCGT, to estimate
the risk of insertional oncogenesis, and finally by secondary trans-
plantation, a useful pre-clinical tool to detect vector induced hemato-
logical transformations.26,27 Woodchuck posttranslational regulatory
element (WPRE) mRNA and TP protein levels were detectable in
PGK-TP and TPco-transduced Lin cells (Figures 1C and 1D), and
TP enzyme activity was enhanced in Lin cells, granulocyte-mono-
cyte progenitors, and 293T cells (Table S1). The two vectors were
used interchangeably and referred to as PGK-TP(co) hereafter.
Biochemical Correction and Molecular Chimerism following
Ex Vivo HSCGT
Stable blood TP activity was observed both in the PGK-TP-GFP
group as previously reported20 and in recipients of the therapeutic
LV-PGK-TP(co) (Figure 2A). Lin cells successfully engrafted both
PGK-TP(co) and PGK-GFP recipient KOmice, and integrated vector
copies were detected (Figure 2B; Table S2). We next measured TP
activity in diseased tissues of our mice. Transduction resulted in
increased TP activity to normal levels in brain and small intestine
in the PGK-TP(co)-treated mice (Figure 2C). As a consequence of
the high-TP activity, urine and plasma nucleosides were undetectable
in almost all recipients of PGK-TP(co) with extensive reduction in
brain nucleosides compared to both KO and wild-type (WT) animals
(Figures 2D and S1A). Overall, median nucleoside levels were reduced
insufficiently at the lower MOI (Figures 2D and S1A; MOI 3, range
0.1–0.8 VCN/cell and percentage chimerism 47%–76%, n = 5; Table
S2). Eleven months after transplantation, recipients of PGK-TP(co)
displayed 98% and 57% reduction in median intestinal d-Thd and
d-Urd levels, respectively (Figures 2E and S1B). Moreover, HSCGT
provided high-TP enzyme activity and reduced nucleoside levels in
skeletal muscle and liver (Figure S1C). All together, the transduction
efficiency, integrated vector copies, and engraftment levels determine
the outcome of biochemical correction (Table S2; Figures 2D and
S1A). At an MOI of 3, significant reduction of nucleosides was
observed, full correction of the biochemical phenotype only occurred
at transplantation of 6 Gy irradiated recipients of 5  105 MOI 10
transduced cells, particularly in the small intestine, in contrast to
the previous study.20d transplanted into female recipient mice. To determine the integration site profiles,
ells in vitro and BM cells from transplanted primary mice in vivo; see also Figure S3A.
imary recipient were transplanted into two secondary KO female recipient mice. All
ll experiments included age-matched untreated KO and WT controls. aEnd point
analysis. MRI, magnetic resonance imaging; IHC, immunohistochemistry. (C–E) TP
CR analysis of WPRE mRNA expression normalized to GAPDH levels and corrected
blot of total protein extracts from Lin cells and their content corrected for VCN/cell,
g the higher TP protein with this promoter. (E) TP activity in the cultured Lin cells.
2018
(legend on next page)
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Neurological changes are consistently reported in MNGIE patients,
and minor changes were reported in old Tymp/Upp1/ mice
aged R18 months.22 To characterize neurological abnormalities
at earlier ages and to address the impact of HSCGT as early as at
2 months of age, brain MRI scans and immunohistochemistry
(IHC) were performed. In contrast to WT mice, an increase in per-
centage of fluid content was observed as a hyper-intense signal in
the brains of KO mice aged 6 to 12 months (five out of eight) (Fig-
ure 3A). Increased T2 signals are indicative for fluid accumulation
in the white matter surrounding the lateral ventricles, suggesting
edema. White matter edema was absent in most treated mice;
8 out of 10 treated mice fell in the same hyper-intense volume
range of WT animals (Figure 3B). Brain sections from KO mice
stained with mature myelin proteolipid protein (PLP) and myelin
basic protein (MBP) revealed the presence of progressive vacuoliza-
tion in the cerebellar and cerebral white matter structures absent in
WT mice. White matter vacuolizations were lined and crossed by
thin immunopositive tissue strands, consistent with intramyelinic
edema (Figures 3C and 3D). PLP and MBP staining revealed disap-
pearance of white matter vacuolization in the cerebellar white mat-
ter and corpus callosum of PGK-TP(co)-treated group (Figures 3C
and 3D). IHC staining for the astrocyte-specific glial fibrillary
acidic protein (GFAP) revealed increased thickness of astrocyte
processes abutting the blood vessels in KO mice as young as
2 months, compared with age-matched WT mice, which was
further increased in KO mice aged 12 months (Figures 3E and
3F). The thickness of astrocyte perivascular processes in cere-
bellum, corpus callosum, and hippocampus white matter of PGK-
TP(co)-treated mice were reduced to normal levels (p < 0.0001)
(Figures 3E and 3F). In addition, GFAP staining of the cerebellar
cortex revealed that Bergmann glia were localized to the molecular
layer in KO mice in contrast to the normal localization in the Pur-
kinje cell layer in WT mice and after treatment (Figure 3G). All
together, brain MRI and IHC revealed the classical morphological
changes in KO mice at a younger age and further demonstrated
an underlying edema linked to changes of the brain astrocytes,
which are reversed upon HSCGT.
Safety Evaluation
Excessive transgene expression-related phenotoxicity and/or geno-
toxicity caused by LV insertional mutagenesis are potential draw-
backs for clinical application of HSCGT. These two issues were not
addressed in previous studies19,20 of HSCGT for MNGIE. A total of
106 controls and primary recipients of 5  105 Lin cells transduced
with therapeutic and GFP LVwere monitored for 11months. SurvivalFigure 2. Long-Term Biochemical Correction and Molecular Chimerism follow
Lin cells were transduced with the therapeutic and control LV vectors at MOI 10, and
(A) TP enzyme activity wasmeasured in blood at months 1 and 11 after transplantation, n
n = 5–9 mice/group. (C) Brain and intestine TP activity were measured 11 months afte
plasma, brain 8–11months after transplantation (MOI 10 or 3), n = 4–11mice/group, and
line represents the median, *p < 0.05, **p < 0.01, and ***p < 0.001; n.s., not significan
156 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchwas not significantly reduced in the group combining PGK-TP or
TPco recipients (70%) compared with PGK-GFP (92%) or untreated
KO controls (94.4%) (Figure S2A). Some recipients of PGK-TP or
TPco were sacrificed and analyzed prematurely because of death or
high discomfort scores. We have been unable to determine the actual
cause of wasting, but importantly, vector-positive hematological
clonal expansion was not observed (Table 1; Figure S2). At termina-
tion, hematopoietic reconstitution between groups was similar,
except for a reduction in numbers of spleen CD3+ T cells in PGK-
TP(co) and peripheral blood CD19+ B cells in SF-TPco-treated
mice (Figure 4; Table S3). Excessive increase in TP activity was de-
tected in Lin cells, granulocyte-monocyte progenitors, and 293T
cells transduced with LV-SF-TPco (Table S4A), in blood and brain
(Table S4B). This increase was substantially higher than in the
PGK-TP and TPco treatment groups (Table S1; Figures 2A and
2C). As expected, nucleosides were not detectable in urine and plasma
and extremely reduced in the brains of SF-TPco mice (Table S4B).
Although percentage donor chimerism in SF-TPco-treated mice
was high (Table S4B), 12 out of 14 primary recipients were sacrificed
prematurely mainly due to severe body weight loss (>15%) observed
at death (n = 6 out of 12). This increased incidence of weight loss was
not observed in PGK-TP or TPco treatment groups (Table 1; Fig-
ure S2). To evaluate genotoxic risk, we analyzed the therapeutic
and GFP containing LV vector integration site profiles in mouse
Lin cells in vitro and in bone marrow (BM) cells from primary recip-
ient mice (Figures 1B and S3). In total, 7,435 unique integration sites
(IS) were retrieved by linear amplification mediated-PCR (LAM-
PCR) and sequencing from 4 in vitro samples and 10 transplanted
mice (Table 2). A polyclonal integration pattern was observed with
1,174 common IS (CIS).28 In total, 225 IS near oncogenes were iden-
tified, accounting for 3.03% of all genes (Table 2). We analyzed the IS
patterns for the oncogene frequency between groups classified based
on promoter, i.e., PGK versus SF, or pre-transplantation lineage nega-
tive cells versus bonemarrow in vivo or transgene GFP versus TP (co),
but no differences were observed (Table 3). To assess genotoxicity
further, BM Lin cells from primary recipients (n = 44) were trans-
planted into 88 secondary recipients. In both the primary and second-
ary recipients, we did not observe any vector-positive hematological
clonal expansion in the therapeutic PGK-TP or PGK-TPco groups
(Table S5). In nine recipients of cells LV transduced by PGK-GFP,
TP, TPco, and SF-TPco, vectors altered leukocyte levels and counts
revealed hematological aberrations. These cases had very low median
vector copy number (VCN)/cell (0.03 with range 0.01–0.07) and
donor chimerism (0.7% with range 0.2%–7.1%, n = 8; Table S5)
and therefore were classified as non-vector-related. Two PGK-TP-
GFP recipients of Lin cells of a single primary mouse developeding HSCGT
5  105 cells were transplanted into six Gy pre-conditioned 2-month-old KO mice.
= 3–9mice/group. (B) BM cell chimerism and vector copy number of recipient mice,
r transplantation, n = 3–12 mice/group. (D) Quantification of Thd in urine, d-Thd in
(E) in intestines 11 months after transplantation, n = 3–9 mice/group. The horizontal
t. Mice in the PGK-TPco treatment group are identified (square symbols).
2018
(legend on next page)
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Number of Prematurely Dead Mice or Mice
Sacrificed with High Discomfort Scoresb
WT CTR (n = 13) 0 0 0
KO CTR (n = 18) 0 0 1 (macrocephaly)




PGK-TP-GFP (n = 6) 0 0 0




1 (epileptic seizure during behavioral test)
2 (found dead)
1 (body weight loss)d
PGK-TPco (n = 11) 0 0
1 (epileptic seizure during behavioral test)
1 (found dead)
2 (passive)
SF-TPco (n = 14) 0 0
5 (body weight loss)





Mice were transplanted with LV transduced 5  105 BM Lin cells (MOI 10) and followed for 11 months after transplantation. CTR, control untreated mice.
aHematological aberrations and clonal expansion of transduced cells were assessed based on altered FACS phenotypes and/or elevated WBCs, and/or enlarged spleen, thymus, or
lymph nodes. BM was tested for male donor cells and vector copy number.
bThe right column includes mice that were found dead or mice sacrificed prematurely during the experiment due to high discomfort scores and for which hematological aberrations
could not be identified (details are specified between parenthesis).
cPGK-GFP group includes recipient mice of KO or WT Lin cells transduced by PGK-GFP.
dBody weight loss at the time of death >15% over a time span of 1 to 2 months.
Molecular Therapy: Methods & Clinical Developmentvector-positive diffuse intermediate to large B220+GFP+ B cell lym-
phoma (Table S5) at 9 and 11 months after transplantation. The
VCN/cell and percentage chimerism were 0.86 and 67% in one mouse
and 0.76 and 48% in the other mouse. An abundance of abnormallyFigure 3. Brain Magnetic Resonance Imaging and Characterization of Brain W
Lin cells were transduced with the therapeutic LV vectors at MOI 10, and 5 105 Lin c
were performed on 2-month-old (young controls) and 6- to 12-month-old controls and tr
voxels within the brain (white dotted) were quantified by using a reference ROI (red do
edema. The data displayed is the percentage of voxels with high signal intensity of t
Immunohistochemical staining was performed on brain tissue collected from young cont
transplantation, n = 4 mice. (C) Staining for the mature myelin protein proteolipid protein
KO and WT female mice shows normal myelin amounts in the cerebellar white matter o
cerebellar whitematter of KO animals. The horizontal line represents themedian, *p < 0.0
protein (MBP) of the corpus callosum shows myelin pallor in KO compared to WTmice, w
of PGK-TPco transduced HSCs is shown. (E) Staining for the astrocyte-specific inter
processes abutting the blood vessels in the cerebellar white matter of KO mice as young
Labeling against GFAP shows thinner perivascular astrocytic processes in the brain o
surrounding blood vessels, nR 56 processes/group. The horizontal line represents the
protein glial fibrillary acidic protein (GFAP) shows that Bergmann glia (arrows) are locate
PGK-TPco transduced HSCs (left and right, respectively), whereas in KO mice, they ar
158 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchlarge B cell population of B220+GFP+ cells was observed in BM (Fig-
ure S4A) of both mice, i.e., >80% of total BM cells (Table S5), spleen,
and peripheral blood of one mouse. Pathological analysis showed
infiltration of malignant B cells in spleen and liver (Figure S4B).hite Matter Damage and Rescue by HSCGT
ells were transplanted into six Gy pre-conditioned 2-month-old KOmice. MRI scans
eatedmice. (A) Representative T2 scans ofWT, KO, and treatedmice. Hyper-intense
tted). (B) Results of the quantification of cerebrospinal fluid (CSF) and white matter
he whole brain, n = 6–10 mice/group. The horizontal line represents the median.
rols and 12-month-old controls, n = 2–3/group, and treated mice 9–10 months after
(PLP) of cerebellum of young (left and right at higher magnification) and old (middle)
f a PGK-TP-treated mouse. Quantification shows significantly more vacuoles in the
5, **p < 0.01, and ***p < 0.001. (D) Staining for themature myelin proteinmyelin basic
hich is rescued after gene therapy in treated female mice; a section from a recipient
mediate filament protein glial fibrillary acidic protein (GFAP) shows thicker cellular
as 2 months compared to WT mice. The asterisk indicates the blood vessel lumen.
f a recipient of PGK-TPco transduced HSCs. (F) Thickness of astrocyte processes
median, ***p < 0.0001. (G) Stain against the astrocyte-specific intermediate filament
d in Purkinje cell layer (PCL) of the cerebellar cortex of WT and a recipient mouse of
e mislocalized to the molecular layer (ML) (middle); GL, granular layer.
2018
Figure 4. Hematopoietic Reconstitution after
HSCGT
The following analyses were performed 9–11 months
after transplantation of Lin cells transduced at MOI 10.
(A) FACS analysis of peripheral blood, bone marrow, and
spleen cells. Cells were stained with antibodies against
CD45.2 and CD3, CD19, and CD11b for detection of,
respectively, T, B, andmyeloid leukocytes (n = 3–12mice/
group). The horizontal line represents the median; *p <
0.05, **p < 0.01. (B) Colony-forming unit assay. BM cells
were cultured and granulocyte-monocyte progenitors
(CFU-GM) were counted, n = 1–6 mice /group. The hor-
izontal line represents the median.
www.moleculartherapy.orgThe B cell clone contained a single dominant integration site (IS) in
the chromosome 11 gene Zfp207. No known oncogenes were found
within 500 kb of this IS (Figure S4C). Of note, the primary donor
mouse had two dominant IS located in the genes Aplp2 on chromo-
some 9 and Csmd3 on chromosome 15, but the Zfp207 IS was not de-
tected by LAM-PCR. Primer-specific PCR amplification confirmed
very low presence of this IS in bone marrow and spleen (data not
shown). Besides the miscellaneous symptoms observed in therapeutic
PGK-TP(co)-treated mice, which are not likely to be related to the
gene therapy procedure, incidence of phenotoxicity was observed in
the SF treatment group, i.e., severe weight loss in the majority of
the treated cohort. Hematological abnormalities or increased risk ofMolecular Therapy: Methods &insertional mutagenesis were not observed in
the group of mice receiving the therapeutic
vectors.
DISCUSSION
The present study, using a clinically applicable
self-inactivating transfer vector (SIN) LV vector
with a modified WPRE and without GFP and
a highly efficient, overnight gene transfer
procedure, demonstrates not only full biochem-
ical correction, but, importantly, also com-
plete clearance of intestinal nucleosides and
a remarkable phenotype correction in the
brain of Tymp/Upp1/ mice. Overall, the
biochemical correction obtained in blood and
tissues reported earlier by using PGK-TP-
GFP20 was confirmed here in a larger cohort
of mice by using the therapeutic vectors LV-
PGK-TP(co). The additional complete clear-
ance of intestinal nucleosides and remarkable
phenotypic correction in the brain demon-
strates the feasibility of a curative gene therapy
approach for MNGIE patients.
In MNGIE patients, the intestines are severely
affected, resulting in cachexia, severe infections,
and death. The intestine facilitates uptake of nu-
trients possibly requiring high TP enzyme activ-ities to reduce incoming thymidine levels locally. Of note, intestinal
TP activity in WT mice is substantially higher than that in blood
and brain tissue (Figures 2A and 2C), which emphasizes that high
TP activity levels in intestine are likely required to normalize nucleo-
sides. In our study, therapeutically relevant transduction efficiencies
by PGK-TP(co) (median VCN/cell = 1.3, range, 0.2–3.6; Figure 2B;
Table S2) resulted in complete clearance of intestinal nucleosides,
in contrast to the earlier study,20 in which d-Thd was significantly
reduced in plasma and brain, but not in the intestine. In addition
to the high liver and muscle TP activity, this finding of an improved
biochemical correction supports our low vector MOI (3 or 10 versus
10020) and pre-transplant conditioning protocol.Clinical Development Vol. 8 March 2018 159











Lin (KO) PGK-TP 2 3,147 102 3.24




PGK-GFP 2 782 20 2.56
BM
(KO-KO)





3 529 26 4.91
total 14 7,435 225 3.03
Molecular Therapy: Methods & Clinical DevelopmentThe current experiments, performed with high transduction effi-
ciency and dose, resulted in supranormal levels of TP activity and
in near-complete elimination of systemic nucleosides, i.e., below
WT levels, indicating that lower enzyme levels should be sufficient
to correct the biochemical imbalance. For gene-modified and vec-
tor-dose-titration experiments, relatively large cohorts of mice are
required to demonstrate a dose-response relationship. However,
whether or not lower cell and LV dose would be efficient is of doubt,
since the small intestine requires a high cell dose and an MOI of 10
to normalize TP activity and nucleosides (Figures 2C, 2E, and S1B).
The absence of a clear clinical phenotype is a limitation of the only
murine disease model of MNGIE available, and very scanty patho-
logical findings have been reported, mainly in Tymp/Upp1/
mice aged R18 months.22 In the present study, we observed path-
ological white matter changes in KO animals as early as 2 months of
age and MRI changes at 6 months of age, which recapitulate the
findings in the brain of MNGIE patients, i.e., white matter edema
without demyelination or gliosis and hyperintense T2-weighted
signal changes.8,29 In this, our mouse model is representative of
the human MNGIE syndrome. Importantly, HSCGT resulted in
elevated TP activity and restored brain white matter integrity and
reduced edema as evident by both MRI and IHC. Another study
on MNGIE patients demonstrated that loss of brain TP was associ-
ated with loss of blood-brain barrier integrity, which resulted in
activation of astrocytes.30 We showed increased astrocytic process
thickness in Tymp/Upp1/ mice, which is limited to the cell pro-
cesses abutting blood vessels. This argues against reactive astroglio-
sis and rather suggests swelling of the astrocyte perivascular endfeet.
Such a phenotype might be responsible for the observed progressive
intramyelinic edema in Tymp/Upp1/ mice as reported in other
white matter diseases31 and could be explained by an interference
with the normal function of astrocytes in maintaining ion-water ho-
meostasis.32 The latter finding prompts further research aimed at
investigating the molecular mechanisms underlining brain patho-
physiology in MNGIE, as this knowledge could be exploited for
further therapeutic intervention.160 Molecular Therapy: Methods & Clinical Development Vol. 8 MarchWe did not demonstrate TP-positive hematopoietic cells in the brain,
however, previous murine gene therapy studies using AAV2/8 vec-
tors21 transducing the liver showed reversal of nucleoside imbalance
without the local presence of TP in the brain. However, in HSCGT,
gene-modified monocyte progenitors may migrate to the brain and
differentiate into microglia.33 Since TP is a cytoplasmic protein, we
measure this TP activity in the brain (Figure 2C), indicating that
transduced microglia might reside in the brain after long-term
follow-up.
Despite the brain pathology in Tymp/Upp1/ mice, we could not
detect significant differences in several memory and motor function
assessments, which involved cerebellum, cortex, and hippocampus,
between the Tymp+/+Upp1+/+, Tymp/Upp1/, and gene therapy-
treated mice (data not shown). This could be attributed to differences
in physiology and lifespan between mice andman. Other leukodystro-
phy mouse models, including those for megalencephalic leukoence-
phalopathy with subcortical cysts similarly lack a clinical phenotype
despite the presence of severe pathological abnormalities.31 Similar to
the analysis of MNGIE human brains,30 we did not detect mtDNA
depletion, deletions, or any changes in mtDNA topology or strand
breaks. Although the variation between individual mice is large,
Tymp/Upp1/ and treatedmice showed signs of replication stalling
in brain tissue (data not shown), which requires further investigation.
Of major concern, as yet unaddressed, is the potential transgene or
LV-related phenotoxicity or genotoxicity. The results indicate that
overexpression has no direct effect on hematopoietic system. First,
we did not observe loss of vector-transduced cells in the hematopoietic
compartment or donor-derived cells (Figure 2B; Table S2). Second,
blood TP activity was not extremely reduced 11 months after trans-
plantation (Figure 2A), so there is no clear selection for low expressor
cells. Finally, there was no difference in the polyclonality betweenGFP
and therapeutic vectors in vitro and 11 months after transplantation
and therefore no apparent reduction in the number of integrated
vector (Table 2). The toxicity is not related to the LV vector, since
LV-PGK-GFP did not show toxicity (Table 1; Figure S2). Additionally,
the higher death rates with the clinical vector included only onemouse
that had wasting. For the other deaths, the symptoms or potential
causes of death were miscellaneous. Only when highly overexpressed
by the SF vector was the main observation before death the wasting
(Table 1; Figure S2). Therefore, we assume that the observed toxicity
is related to the excessively expressed TP by the strong SF promoter
and the increased mortality (Table 1; Figure S2A) likely due to com-
plete elimination of d-Thd and/or d-Urd affecting downstream mito-
chondrial dNTPs. dNTP pool imbalance triggers cell cycle arrest and
apoptosis in vitro in hematopoietic cell lines and yeast variants,34,35
which, however, needs further investigation in Tymp/Upp1/
mice. Using the therapeutic vectors, oncogenic adverse effects were
not observed after a total follow-up in primary and secondary recipient
mice of 22 months, demonstrating the safety profile of PGK-
driven TP expression. A single, possibly insertional, oncogenic event
was observed in the PGK-TYMP-IRES-GFP-treated mice. Two
secondary recipients acquired the same B cell lymphoma clone with2018
Table 3. Summary of LV IS Classified Based on Promoter, Cell Type, and Transgene
Group Number of Samples Number of IS Unique Genes CIS Unique Oncogenes Number of Oncogenes % Oncogenes
All 14 7,435 4,104 1,174 110 226 3.03
PGK only 12 4,946 3,082 702 87 152 3.07
SF 2 2,489 1,869 241 52 74 2.97
Lin (in vitro) 4 5,636 3,408 815 102 177 3.14
BM (in vivo) 10 1,799 1,379 178 35 49 2.72
GFP only 2 782 666 48 17 20 2.56
TP (co) 12 6,653 3,799 1,030 106 206 3.10
www.moleculartherapy.orgthe PGK-TP-GFP vector integrated near theZfp207 gene, which could
be traced back to one primary recipient mouse. Zfp207 or its human
homolog is not reported as a proto-oncogene but has a role in cell cycle
and mitotic nuclear division: in particular, ZFP207 is required for
proper chromosome alignment,36 and Zfp207 knockdown has been
associated with lethal chromosome congression defects in trans-
formed cells.37 The B cell lymphoma contained a LV integration
with an early version Woodchuck hepatitis virus posttranslational
regulatory element (PRE). Although reports have never shown un-
equivocally that the use of such a PRE carries additional insertional
oncogenic risks, our therapeutic LV vectors contain amutated element
(bPRE4*) to reduce risks further.38 Since the lymphomas in the sec-
ondary transplanted mice were identical, the oncogenic event neces-
sarily occurred in the primary transplanted mouse. The integration
near the Zfp207 gene might have contributed to the development or
expansion of this clone, but it is not excluded that the observed lym-
phoma is not related to vector integration at all, which would require
further investigation of potentially oncogenic mutations.
In summary, the therapeutic PGK-TP(co) vectors provided sufficient
expression for biochemical and phenotypic correction without detect-
able phenotoxicity and a favorable safety profile, similar to the LV
vectors currently in clinical trial for other inherited disorders. None-
theless, excessive TP expression in the LV-SF treatment group, not in-
tended for clinical application, resulted in reduced survival (Table 1;
Figure S2), a finding in need of further investigation and underlining
the requirement of a moderately strong housekeeping gene promoter
such as PGK for clinical application in MNGIE, possibly in combina-
tion with low-intensity or non-myeloablative conditioning.
It is concluded that the present study warrants further development
including cell and vector dose-response experiments with a larger
cohort of mice, biodistribution studies, and assessment in human he-
matopoietic cells to substantiate any claims that the therapeutic vec-




The SIN pCCL-hPGK-TP-IRES-GFP-WPRE was described before
and is used in our study as a control.19 The human TYMP sequenceMoleculfrom this LV vector, a re-coded TYMP sequence (human TPco,
GenScript, Piscataway, NJ, USA)24 with optimized open reading
frame (Genscript algorithm) with a consensus Kozak sequence and
an additional stop codon, and the green fluorescent protein GFP
sequence were all cloned into the pRRL-SIN-bPRE4* backbone under
the human PGK promoter.38 Human TPco was also cloned under the
SF promoter (Figure 1A). Third-generation packaging plasmids
pMDL-g/pRRE, pRSVREV and envelop plasmid pMD2-VSVg were
used.39 LV vectors were generated by calcium-phosphate precipita-
tion of HEK293T cells.40 Forty-eight hours after transfection, LV vec-
tors were concentrated by ultracentrifugation at 20, 000 rpm for 2 hr
at 4C and the pellets resuspended in PBS. LV vector titration was
performed on HeLa cells. After 72 hr, cells were analyzed on an
LSR-II flow cytometer and FACS diva software to calculate the titers
of a GFP containing batch. Titers of TP and TPco containing vectors
were determined by qPCR.
HSC Transduction and Primary and Secondary Transplantation
The generation of Tymp/Upp1/ (KO) and Tymp+/+Upp1+/+
WT mice on a C57BL/6J genetic background have been described
before.22 The animals were bred in the Erasmus MC Experi-
mental Animal Center (Rotterdam, the Netherlands). During
the experiments, mice were kept in filter top cages, fed with auto-
claved water, and irradiated chow ad libitum. The animal experi-
ments were reviewed and approved by an ethical committee of
Erasmus MC, Rotterdam in accordance with legislation in the
Netherlands.
Bone marrow cells were harvested aseptically from femurs and tibiae
of 4- to 19-week-oldmale mice by flushing with PBS, followed by line-
age depletion (Lin) according to manufacturer recommendations
(BD Biosciences). Lin cells were cultured overnight in the presence
of the LV vector constructs at an MOI of 10 or 3 in serum-free modi-
fied Dulbecco’s mediumwith supplements41 and stimulated with mu-
rine stem cell factor (SCF; 100 ng/mL), human FMS-like tyrosine
kinase 3 ligand (Flt3-L, 50 ng/mL), murine thrombopoietin (TPO,
20 ng/mL). Subsequently, Lin transduced cells (5  105) were in-
jected into the tail vein of 4 to 17 weeks of age recipient KO or WT
female mice, subjected to six Gy irradiation 24 hr prior to transplan-
tation. For the secondary transplantation, similarly each of two 5- to
14-week-old KO female recipients were transplanted with 2  105ar Therapy: Methods & Clinical Development Vol. 8 March 2018 161
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gle primary recipient mouse (Figure 1B).
Sample Collection, Analysis, and Termination of Experiments
During the course of experiments, primary, and secondary recipient
mice were monitored carefully for any signs of discomfort. Body
weights and leukocyte phenotypes were measured monthly up to
6 months post-transplantation in some primary recipients. Complete
blood cell counts (CBCs) and leukocyte phenotypes of secondary re-
cipients were monitored 3 months after transplantation. When appli-
cable, blood and urine samples for biochemical analysis were
collected. Mice were removed from experiments if they appeared
ill, had severe body weight loss of >15%, had changes in behavior,
or for other reasons, for example malocclusion or fight wounds.
The following analyses were performed at experimental end point
or at death when possible. EDTA peripheral blood and urine samples
were collected on ice and stored at 80C for biochemical analysis.
Mice were sacrificed by inhalation of a CO2/O2 mixture and were
transcordially perfused with PBS. The following was performed:
assessment of body weights, physical appearance, presence of abnor-
mality such as pale feet, rectal prolapse, injuries, lumps (tumors,
cysts), visual examination of major organs (heart, lung, brain, liver,
kidney, gastrointestinal tract, spleen, thymus, lymph nodes), docu-
mentation of organomegaly (spleen, thymus, lymph nodes), and pro-
cessing of samples from lesions and enlarged organs for H&E stain-
ing/IHC. Tissue samples were snap-frozen in liquid nitrogen and
stored at80C for biochemical analysis. CBCs were measured using
automated equipment (scil Vet ABC Hematology Analyzer, Gurnee,
IL). Leukocytes, spleen cells, and fractions of total bone marrow were
used for FACS analysis. In some experiments, bone marrow cells
were cultured to assess progenitor cell content by colony assays. Al-
iquots of bone marrow cells were stored at 80C for molecular
analysis as described below, and the remainder of the bone marrow
cells was cryopreserved for retransplantation. For testing the risk of
insertional oncogenesis, hematological aberrations were based on
abnormal FACS phenotype of at least one of the hematopoietic tis-
sues, BM, spleen, or peripheral blood and/or white blood cell counts
(WBC) (further analyzed for leukemia in case WBC > 25.0  103
cells/mL) and /or enlarged spleen, thymus, or lymph nodes. The he-
matological aberration was considered a potential oncogenic clone if
both donor cells and VCN were prominent in the recipient’s BM
sample.
Flow Cytometry
Erythrocytes were removed with lysis buffer (0.15 M NH4Cl, 0.1 M
EDTA), and leukocytes, bone marrow, and spleen cells were washed
with Hank’s balanced salt solution (Invitrogen) containing 0.5% (w/v)
BSA and 0.05% (w/v) sodium azide (HBN) followed by 30 min incu-
bation at 4C in HBN containing 2% heat-inactivated normal mouse
serum and antibodies against CD45.2, CD3, CD19, and CD11b,
directly conjugated respectively to APC-Cy7, APC, PE, and PerCP-
Cy5.5; or, against CD8, CD45R/B220, Gr-1, c-Kit or CD4, IgD,
CD19, Sca-1 or CD3, IgM, CD11b, directly conjugated respectively
to APC, PE or PerCP (Cy5.5) (BD Biosciences and Biolegend, Lon-162 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchdon, UK). Cells were washed and measured on a Canto or LSR-II
flow cytometer (BD Biosciences).
Progenitor Cell Assay
To detect colony-forming unit granulocyte monocyte (CFU-GM),
5  104 total bone marrow cells in 10% of the total volume were
seeded in semisolid methylcellulose in 80% of the total volume
(MethoCult M3231, Stem Cell Technology, France) with 10% of the
total volume of Iscove’s modified Dulbecco’s medium (IMDM) sup-
plemented with rm-SCF (100 ng/mL), rm-interleukin-3 (30 ng/mL)
and rm-GM-CSF (30 ng/mL) (R&D Systems). Cultures were incu-
bated at 37C in a humidified atmosphere containing 5% CO2, and
colonies were scored 7 days later under an inverted microscope.
Biochemical Analysis of TP Enzyme Activity and Nucleoside
Levels
TP enzyme activity in blood cells, tissue samples, and plasma d-Thd
and d-Urd levels were measured by liquid chromatography (UPLC-
UV), while tissue d-Thd and d-Urd levels were measured by
liquid chromatography-mass spectrometry (HPLC-MS) as described
before.19,21 Urinary Thd and d-Urd were measured by HPLC.42 Urine
samples were thawed to room temperature by incubation at 37C for
30 min prior to measurement of concentrations. One volume of
sample plus 1 volume of internal standard solution was diluted
with 1 volume of eluent A (30 mM ammonium acetate, 1% methanol
[pH 4.80]). The samples were incubated at 60C for 30 min, followed
by centrifugation on filter units at room temperature at 13,000 g for
20 min. Twenty microliters of filtrates were then injected into an
HPLC system (Shimadzu, LC20 series with a binary pump and Photo-
diode array detector), equipped with an Alltima C18 5m, 250 mm 
4.6 mm column and Alltima C18 5m guard column. Chromatography
was performed as described previously.42 Concentrations were calcu-
lated by comparison of the Thd and d-Urd peak areas in samples to
the corresponding peak areas of standards using caffeine as an inter-
nal standard to correct for injection volume. Creatinine concentra-
tions of the samples were measured in the same runs.
qPCR and Western Blotting
KO Lin cells were transduced by PGK-TP, PGK-TPco, or SF-TPco
(MOI 10) and cultured in vitro for 7 days. Total RNA was extracted,
and 1 mg was reverse transcribed into cDNA (RNeasy MicroKit and
QuantiTect Reverse Transcription Kit, QIAGEN, Hilden, Germany)
following manufacturer’s instructions. Genomic DNA isolation
from both cultured Lin cells and bone marrow cells was performed
by using NucleoSpin Tissue kits (Bioké, Leiden, the Netherlands)
following manufacturer’s protocol. RNA and DNA concentration
and purity were determined by using Nanodrop (Nano Drop
1000Spectrophotometer). Template cDNA and 100 ng template
genomic DNA were subject to qPCR by using SYBR Green PCR
master mix and the primers described before26,43,44 and summarized
in Table S6 (Applied Biosystems, Foster City, CA; Eurogentec,
Maastricht, the Netherlands). The PCR reactions were carried out
in the ABI7900 Taqman machine, and results were analyzed with
SDS2.2.2 software (Applied Biosystems). The average vector copy2018
www.moleculartherapy.orgper cell were calculated by comparing the cycle threshold values ob-
tained against a standard curve obtained from mouse 3T3 or HeLa
cells, and to calculate Y chromosome chimerism a standard curve
was obtained from male mouse bone marrow samples.
Western blotting was performed by using Novex midi gel system for
electrophoresis and blotting (Invitrogen, Carsland, CA) following
manual’s instructions. Cultured Lin cells were lysed by sonication,
protein concentrations were determined by using BCA protein assay
kit (Thermo Fisher), and a total of 15 mg proteins were separated by
4%–12% Bis-Tris SDS-PAGE, transferred to nitrocellulose and PVDF
membranes and blotted with primary and secondary antibodies
(summarized in Table S7), and finally signals were detected with
enhanced chemiluminescent substrates detection kit (Thermo
Fisher). ImageJ software was used to quantify protein levels.
Vector IS
In order to identify vector IS, vector LTR-genome junctions were
amplified by LAM-PCR as previously described.45,46 In brief, after
linear amplification with biotinylated LTR-specific primers, amplifi-
cation products were purified using streptavidin magnetic beads.
The following steps included complementary strand synthesis, paral-
lel digestion with three different restriction enzymes (Tsp509 I,
HpyCH4 IV, and Aci I), and ligation to a linker cassette. The frag-
ments generated were then amplified by two additional exponential
PCR steps. LAM-PCR products were separated by gel electrophoresis
on Spreadex high-resolution gels (Elchrom Scientific), underwent a
fusion PCR for the addition of barcoded adaptors, were pooled into
libraries, and were Illumina sequenced (MiSeq) as previously
described.47 The resulting sequences were processed through a
customized informatics pipeline (Biasco et al.46; L. Leonardelli
et al., 2016, ASGCT, abstract), which performs cleaning for quality
and collisions, mapping, and annotating of IS on the mouse genome
(December 2011, GRCm38/mm 10).
mtDNA Analysis
MtDNA copy number, conformation, and integrity were evaluated in
total and mitochondrial DNA extracted from tissue samples.48,49 In
brief, mtDNA copy number was determined by real time-PCR using
primers and Taqman probes for mitochondrial and NDUVF1 and the
AccuStartII PCR supermix (QuantaBio). The respective primer se-
quences are summarized in Table S6. To quantify the levels of existing
mtDNA strand breaks, mitochondrial DNA and free 30 ends were
labeled in vitro using radioactive incorporation of dCTP by terminal
deoxynucleotide transferase. 0.5 mg of purifiedmtDNAwas incubated
with 5 mCi dCTP (3000 Ci/mmol) and 7.5 U terminal deoxynucleo-
tidyl transferase (TdT) in 30 mL 1 TdT buffer at 37C for 30 min
and separated over a 1% Tris-borate-EDTA (TBE)/agarose gel con-
taining 0.1 mg/mL ethidium bromide. Equal loading was confirmed
by UV visualization, the gel was Southern blotted onto Hybond-XL
membrane, and the intensity of each lane was quantified by phosphor
imaging (Molecular Imager FX, Bio-Rad). The abundance of replica-
tion intermediates was visualized using Brewer/Fangman 2D neutral/
neutral agarose electrophoresis. MtDNA deletions were detectedMoleculby long-range PCR as previously described50 and visualized by
Phosporimager.
MRI
Imaging was performed on a 7.0 T dedicated animal scanner (Discov-
ery MR901, Agilent Technologies/GE Healthcare) using a 4-channel
surface receiver coil (Rapid MR International, Ohio, USA) and a
72-mm transmit body coil. Single-shot fast-spin echo (SSFSE) images
were acquired with settings repetition time/echo time (TR/TE) =
1,600/8 ms, field of view (FOV) = 5 cm, voxel size 0.2  0.2 
1 mm. T2 images were additionally acquired using a fast pin echo
sequence for anatomical reference, settings TR/TE = 2,500/25 ms,
FOV = 5 cm, voxel size 0.2  0.2  1 mm.
Image analysis was as follows: The SSFSE is very sensitive for high
liquid content and therefore, by using these images, the signal inten-
sity (SI) of voxels with high liquid content is much higher than that of
other tissue. This allowed us to determine the fraction of edematic tis-
sue by selecting voxels through thresholding after segmentation of the
whole brain. The threshold was determined by quantifying normal
tissue values by determining a reference region of interest (ROI)
within normal brain tissue. This ROI was manually drawn in a slice
of brain without hyper-intense areas. Voxels with SI of 4 standard de-
viations above the reference ROI SI were considered to have high
liquid content (4 SD = 99.9% confidence interval). The analysis was
performed using in-house developed software based on MATLAB
(MathWorks, Natick, MA, USA).
IHC
Mice were euthanized by inhalation of a CO2/O2 mixture and trans-
cardially perfused with PBS to remove blood. Brains were extracted
and immersion-fixed in 4% paraformaldehyde for 24 hr, paraffin-
embedded, and cut longitudinally to obtain 6-mm-thick sections.
Staining was performed as previously described.31 Antigen retrieval
was performed by treatment with 0.01 M citrate buffer (pH 6.00) in
a steamer and endogenous peroxidase blocked with 0.3% H2O2
in methanol. Sections were blocked in 5% normal goat serum then
incubated overnight at 4C with the primary and secondary anti-
bodies summarized in Table S7. Immunoreactivity was detected
with 3-30-diaminobenzidine as chromogen. Sections were finally
counterstained with hematoxylin and visualized under a Leica
DM6000B microscope. Omitting the primary antibodies yielded no
significant staining. Image series from brain sections stained with
H&E or against protein PLP or the GFAP were obtained with
a 40 objective. Quantification of vacuole and astrocyte morphology
was performed blind to the genotype using ImageJ. The percentage of
cross-sectioned area occupied by vacuoles was quantified in the cere-
bellar and callosal white matter. The thickness of perivascular
astrocytic cell processes at the maximal width was measured.51
Statistical Analysis
Significance of differences between groups was determined by two-
tailed Mann-Whitney U test. Data was graphed and analyzed by
Graph Pad-Prism5 software (version 5.03).ar Therapy: Methods & Clinical Development Vol. 8 March 2018 163
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